Compare
Alumis Inc. vs Earth Science Tech, Inc. vs Sunshine Biopharma Inc. vs Lftd Partners Inc.
| Latest fiscal year | Alumis Inc. ALMS | Earth Science Tech, Inc. ETST | Sunshine Biopharma Inc. SBFM | Lftd Partners Inc. LIFD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $24.05M | $35.70M | $36.31M | $36.92M |
| Revenue growth (YoY) | n/a | +7.8% | +4.1% | -1.1% |
| Gross margin | n/a | 71.4% | 33.8% | 34.2% |
| Operating margin | n/m | n/a | -17.2% | 2.5% |
| Net margin | n/m | 10.2% | -16.5% | -67.3% |
| Net income | -$243.32M | $3.63M | -$5.98M | -$24.86M |
| EPS (Diluted) | -$2.86 | $0.012 | n/a | -$1.68 |
| Operating cash flow | -$369.52M | $1.94M | -$5.33M | $1.32M |
| Free cash flow | -$370.18M | $1.18M | -$5.51M | $1.20M |
| Cash & equivalents | $89.67M | $796.8K | n/a | $1.77M |
| Total assets | $411.94M | $8.97M | $30.08M | $19.27M |
| Total liabilities | $110.64M | $1.93M | $7.04M | $6.64M |
| Shareholders' equity | $301.30M | $7.01M | $23.04M | $12.63M |
| Return on year-end equity | -80.8% | 51.8% | -25.9% | -196.8% |
| Shares outstanding | n/a | 291.32M | 4.91M | 14.82M |
Revenue, most recent five fiscal years
| Fiscal year | Alumis Inc. | Earth Science Tech, Inc. | Sunshine Biopharma Inc. | Lftd Partners Inc. |
|---|---|---|---|---|
| Latest | $24.05M Ended 2025-12-31 | $35.70M Ended 2026-03-31 | $36.31M Ended 2025-12-31 | $36.92M Ended 2025-12-31 |
| 1 year earlier | n/a | $33.12M Ended 2025-03-31 | $34.87M Ended 2024-12-31 | $37.33M Ended 2024-12-31 |
| 2 years earlier | n/a | $11.95M Ended 2024-03-31 | $24.09M Ended 2023-12-31 | $51.61M Ended 2023-12-31 |
| 3 years earlier | n/a | $48.5K Ended 2023-03-31 | $4.35M Ended 2022-12-31 | $57.42M Ended 2022-12-31 |
| 4 years earlier | n/a | $14.1K Ended 2022-03-31 | $228.4K Ended 2021-12-31 | $31.66M Ended 2021-12-31 |